Cytochrome b 5 (b 5 ) is increasingly recognized to be of importance for specific cytochrome P450 (CYP) activities. We developed human b 5 /CYP-competent mutagenicity tester bacteria to study the role of b 5 in the bioactivation activity of human CYP. These new tester bacteria were derived from the previously engineered human CYPcompetent Escherichia coli K12 tester strain MTC, containing a bi-plasmid system for the co-expression of a specific CYP form (CYP1A2, 2A6 or 2E1) with human b 5 , and human NADPH cytochrome P450 reductase (RED), resulting in the strain BTC-b 5 -1A2, BTC-b 5 -2A6 and BTC-b 5 -2E1, respectively. The relative content of b 5 with CYP and RED in these three BTC-b 5 -CYP strains demonstrated physiologically relevant co-expression levels and typical CYP-specific activities could be determined with their specific chemical probes. These strains were applied in mutagenicity assays along with their corresponding b 5 -void strains to determine the effect of b 5 on the CYP1A2-, CYP2A6-and CYP2E1-mediated bioactivation of several promutagens. For CYP1A2, of the 5 compounds tested [2-aminoanthracene (2AA), 1-aminopyrene, 6-aminochrysene, 2-amino-3-methylimidazo(4,5-f )quinoline and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)], only the mutagenicity of 2AA was slightly increased (~1.5-fold) in the presence of b 5 . The CYP2E1-and CYP2A6-dependent mutagenicity of N-nitrosodiethylamine increased~3-and 23-fold, respectively when the bacteria contained b 5 . The CYP2A6-mediated mutagenicity of NNK increased~9-fold when co-expressed with b 5 . The stimulatory effect of b 5 on the bioactivation of N-nitrosodin-propylamine was most striking. The mutagenicity of this procarcinogen was completely dependent on the co-expression of b 5 with CYP2A6 or CYP2E1. This demonstrates the prominent role of b 5 in the bioactivation of this carcinogen.
Introduction
Cytochrome P540 (CYP) enzymes catalyze the oxidation of a large number of endogenous compounds, constitute a major determinant of the half-life and pharmacological properties of therapeutic drugs and are involved in the bioactivation of many drugs, toxins and carcinogens to their ultimate reactive species (1) . The genes encoding the CYP forms involved in xenobiotic metabolism are largely polymorphic, in contrast to those involved in the metabolism of endogenous compounds (2) . Polymorphisms of CYP genes are believed to be responsible for the development of a significant number of adverse drug reactions, in the inefficacy of drugs (2, 3) and may influence the risk of cancer through the modulation of the generation of reactive intermediates (4) .
In vitro assays, using cell systems, which contain a discernible bioactivation parameter and simultaneously allow the expression of human biotransformation enzymes, are considered to be a valuable tool to evaluate the role of human biotransformation enzymes, in particular CYPs and their polymorphic forms in xenobiotic metabolism (5--7) .
We reported previously on the development of a bi-plasmid system for the co-expression of human NADPH cytochrome P450 reductase (RED) with a particular human CYP form in Escherichia coli strain MTC (8, 9) and BTC (M.P.Duarte, B.Brito Palma, A.Laires, J.Santos Oliveira, J.Rueff and M.Kranendonk, unpublished data). These strains were developed for the study of the role of individual CYPs in the bioactivation of chemicals to mutagens, monitored by the reversion to l-Arginine auxotrophy.
Lately, another heme protein is recognized to be of importance for the CYP-mediated reactions, namely cytochrome b 5 (b 5 ). The role of this protein in CYP reactions is thought to involve: (i) direct transfer of a rate-limiting electron, (ii) complexing with CYP to allow a two-electron transfer during a single interaction with RED, (iii) diminution of the extent of uncoupling or (iv) direct effector actions, enhancing product formation without redox changes of b 5 (10) .
In vitro experiments, with purified recombinant enzymes or with cells co-expressing b 5 with RED and CYP, showed that b 5 could modulate specific activities of several CYPs. CYP3A4 (11--14) , CYP2C9 (13, 14) , CYP2A6 (14) and CYP2E1 (13--17) seem to be stimulated by b 5 or, with the exception of CYP2E1, by apo-b 5 . In several cases, the effect of b 5 is not only CYPdependent but also substrate-dependent (11) . On analyzing the effects of apo-b 5 on CYPs activities, it seems plausible that in addition to the involvement in electron transfer, b 5 also plays a conformational role in the human CYP/RED complex (14, 18) . On the other hand, neither apo-b 5 nor b 5 seems to have any effect on CYP1A1, CYP1A2, CYP2D6 or CYP1B1 activities (14) .
Recently, two studies were published describing the co-expression of human b 5 with CYP1A2 and CYP2E1 in a mutagenicity tester bacteria using Salmonella typhimurium LT2. The co-expression of human b 5 with human CYP2E1 and rat RED increased the nitrosamine mutagenicity by as much as 5-fold (15) and the co-expression of b 5 with human CYP1A2 and human RED significantly enhanced the mutagenicity of 2-amino-3,4-dimethylimidazo [4,5- f ]quinoline (MeIQ) (19) . But the expression level of b 5 was not quantified, in both studies hampering the qualification of these systems for their physiological relevance.
The main goal of the present work was the study of the role of b 5 on the bioactivation activities of human CYP1A2, 2A6 and 2E1 in physiologically relevant conditions. For this purpose, we developed a new mutagenicity tester strain (BTC-b 5 -CYP) co-expressing human b 5 with human RED and a specific human CYP form (1A2, 2A6 or 2E1). The cDNA encoding human b 5 was cloned in order to obtain low levels of b 5 expression relative to CYP. These low levels of expression are important, not only to achieve physiologically relevant contents of b 5 , but also to avoid a possible competition between b 5 and CYP for heme in the biosynthesis of these two cytochromes. Recently, it was observed that apo-b 5 is able to remove the heme from CYP3A4 with the formation of holob 5 and apo-CYP (20) , although others have refuted such a possibility (21) . The new strains (BTC-b 5 -1A2, BTC-b 5 -2A6 and BTC-b 5 -2E1) were evaluated for the expression levels of b 5 , CYP and RED, specific CYP enzymatic activities and studies of the role of b 5 on the bioactivation of several procarcinogens by CYP1A2, 2A6 and 2E1. 
Materials and methods

Strains, plasmids and cultures
Strains and plasmids used in this study are presented in Table I . Cloning of human b 5 was carried out as follows. The cDNA encoding human b 5 was amplified from plasmid pT7-7 (22) , excluding the histidine tag region. The cDNA of human b 5 was amplified by PCR using the following primers: GATGAATTCATATGGCAGAGCAGTCGG and CTAGAATTCTCTCCTT-GGTCGA CTCTAGAGG. These primers introduced an EcoRI site (underlined sequence) upstream and downstream of the b 5 coding sequence. The amplification product was ligated in the pGEM-T vector (Promega). The cDNA sequence was verified by automatic sequencing (ABI 310). Finally, the EcoRI insert containing the cDNA for human b 5 was cloned in the EcoRI-digested pLCMhOR (8) , generating plasmid pLCM-b5-RED (Figure 1 ). The correct orientation was confirmed by a restriction analysis.
The development of strains BTC 0 , BTC1A2, BTC2A6 and BTC2E1 will be described elsewhere. Strain PD301 was first transfected with plasmid pLCM-b5-RED and subsequently with the different CYP expression vectors resulting in strains BTC-b 5 -1A2, BTC-b 5 -2A6 and BTC-b 5 -2E1. All strains were verified for the correct phenotype for mutagenicity testing, as described previously (23) . All transfections to tester strain PD301 and derivatives were carried out by the CaCl 2 method (24). For heterologous expression, bacteria were grown at 28 C for 15.5 h in TB medium supplemented with peptone (2 g/l), ampicillin (50 mg/ml), kanamycin (15 mg/ml), chloramphenicol (10 mg/ml), d-aminolevulinic acid (0.1 mM, except for strains with CYP1A2), thiamine (1 mg/ml), a mixture of trace elements (0.4 ml/l) (25) and IPTG (0.2 mM). The cultures were analyzed for their RED-, CYP-and b 5 -expression, CYP activities and subsequently applied as such for the mutagenicity assay.
KanR
Analysis of RED, CYP and b 5 expression
Preparation of bacterial membranes, determination of protein content, CYPand RED-expression, ethoxyresorufin-deethylation, methoxyresorufindemethylation and coumarin-7-hydroxylation activities were performed as described previously (8,9). Chlorzoxazone-6-hydroxylation was measured by reverse phase HPLC according to Pearce et al. (26) . The b 5 content was determined using reduced versus oxidized different spectra (22) , with the modifications described by Voice et al. (12) , in which the background spectrum of endogenous interfering E.coli factors of the membranes lacking b 5 was subtracted from the spectra of b 5 -containing membranes, previously normalized for their protein content.
Bioactivation assays
The mutagenicity assays were performed using the liquid pre-incubation assay technique, as described previously (25) . Experiments were performed at least in triplicate. Revertant colonies were counted after the usual 48 h incubation at 37
C. Mutagenic activities (in revertants/nmol or revertants/mmol) were determined from the slope of the linear portion of the dose--response curve.
Western blot analysis Membrane proteins were separated by 18% sodium SDS--PAGE electrophoresis and electrophoretically transferred onto nitrocellulose membranes (Hybond-ECL Amersham Biosciences). Immunoblotting analyses were carried out with the enhanced chemiluminescent ECL western blotting detection kit of Amersham Biosciences, using polyclonal rabbit anti-rat b 5 primary antibody (20) .
Results
Construction of BTC-b 5 -CYP tester strains
The new BTC-b 5 -CYP tester strains are based on the bi-plasmid expression system (8, 9) for the co-expression of a specific CYP form (1A2, 2A6 or 2E1) with human b 5 , bicistronically co-expressed with human RED. To establish a human b 5 expression plasmid, the cDNA encoding the human b 5 was inserted upstream of the human RED coding sequence in pLCMhOR (Table I ). This newly constructed plasmid (pLCM-b 5 -RED) ( Figure 1 ) and the pCWori-vector containing the cDNA of the three different CYPs were transfected to the mother strain of BTC resulting in strains BTC-b 5 -1A2, BTC-b 5 -2A6 and BTC-b 5 -2E1 (Table I) .
Characterization of RED-, CYP-and b 5 -expression and CYP activities Membranes from cells derived from cultures as used for the bioactivation assays were analyzed for their b 5 , CYP and RED contents (Table II) , as well as their CYP activities (Table III) . Expression levels of both b 5 and CYP could be quantified through spectrophotometric techniques (Figures 2 and 3 (Table II) . The RED content of membranes derived from strains co-expressing RED and CYP2E1 was~2-fold higher than the RED content present in membranes derived from strains co-expressing RED with CYP1A2 or CYP2A6. With respect to the CYP levels, the expression of CYP1A2 and CYP2E1 decreased and the expression of CYP2A6 increased in the strains co-expressing b 5 in comparison with the corresponding b 5 -void strains (Table II) .
To study the effect of b 5 on the catalytic rates of CYP1A2, 2A6 and 2E1, we compared the enzymatic activities with the standard chemical probes of membranes derived from the new BTC-b 5 -CYP strains with those derived from BTC-CYP strains. CYP enzyme activities were determined as ethoxyresorufin deethylase (EROD) and methoxyresorufin demethylase (MROD) for CYP1A2 expressing strains, as coumarin 7-hydroxylase for CYP2A6 expressing strains and chlorzoxazone 6-hydroxylase for CYP2E1 expressing strains (Table III) . (Table III) .
Bioactivation assays
The role of b 5 on the bioactivation activities of CYP1A2, 2A6 and 2E1 was evaluated with several known procarcinogens.
Five different compounds, namely 1AP, 6AC, IQ, NNK and 2AA were tested with strains BTC-b 5 -1A2 and BTC1A2. The mutagenic activities (in revertants/nmol) ranged from 1. from 290 to 2481 revertants/mmol when CYP2A6 was co-expressed with b 5 . The stimulatory effect of b 5 on CYP2A6 and CYP2E1 was most striking with NNdPA (Figures 8 and 9 ). The mutagenicity of this procarcinogen was completely dependent on the presence of b 5 with both these CYPs with a mutagenic activity of 702 and 726 revertants/mmol for BTC-b 5 -2A6 and BTC-b 5 -2E1, respectively.
Discussion
We reported previously on the development of a bi-plasmid system for the co-expression of human RED with a particular CYP form in the E.coli tester strain MTC (8, 9) . E.coli K12 bacteria are devoid of CYPs and can thus be employed for human CYP expression without the interference of endogenous CYPs of other used cell systems (27) .
This study describes the development of three new bioactivation tester strains, namely BTC-b 5 -1A2, BTC-b 5 -2A6 and BTC-b 5 -2E1, by co-expressing human b 5 in the previously established BTC-CYP tester strain. We used these new strains to study the role of b 5 on CYP1A2, 2A6 and 2E1 bioactivation activities with a number of mutagenic compounds.
For all strains, the expression of CYP, RED and b 5 could be quantified (Figures 2 and 3 and Table II It is known that positioning has a significant effect on the expression and activity of proteins encoded by multicistronic plasmids, probably due to the attenuation of transcription and/or translation of the cDNA cloned downstream (15) . With respect to CYP expression levels, b 5 had different effects. The yield of CYP1A2 and 2E1 were lower and that of CYP2A6 was higher, when compared with the corresponding b 5 -void strains for reasons not well understood.
To verify the effect of b 5 on the catalytic activities of CYP1A2, 2A6 and 2E1, membranes derived from strains with and without b 5 co-expression were analyzed with their specific chemical probes. The turnover rates obtained for ethoxyresorufin deethylation and methoxyresorufin demethylation for strain BTC1A2 and for coumarin 7-hydroxylation for strain BTC2A6 were comparable with those obtained previously with MTC strains (9) . The turnover rates for EROD and MROD were higher with membranes derived from strain BTC1A2 than in membranes derived from strain BTC-b 5 -1A2. Previous reports showed that the catalytic activities of CYP1A2 were not affected by the presence of b 5 (13, 14, 17) but could be influenced by the RED:CYP ratio (14) . Strain BTC1A2 presents a RED:CYP ratio 2-fold higher than strain BTC-b5-1A2 and thus, the differences described in this study with respect to the CYP1A2 catalytic rates could be due to the different RED:CYP ratios and not to the presence of b 5 . In this case, it seems likely that b 5 has little or no effect on the EROD and MROD reactions performed by CYP1A2, corroborating the results obtained before by others (13, 14, 17) .
Although having different RED contents, membranes derived from strains BTC2A6 and BTC-b 5 -2A6 presented the same turnover in the coumarin-7-hydroxylation assay. Yamazaki et al. (14) showed that the addition of purified human b 5 , but not of extra membrane-bound RED to E.coli membranes of bacteria expressing RED and CYP2A6, enhanced both the coumarin-7-hydroxylation and the nicotine C-oxidation rates. However, in their study, the RED:CYP ratios ranged from 2.4 to 4, much higher than the RED:CYP ratios in membranes derived from BTC and BTC-b 5 -2A6 strains, which are 0.1 and 0.01, respectively. Our results pertaining to coumarin 7-hydroxylation seems to indicate that either this reaction was not affected by the RED:CYP ratio or that b 5 compensated the lower RED content of BTC-b 5 -2A6 membranes. The rate of chlorzoxazone 6-hydroxylation by CYP2E1 was enhanced 2-fold by b 5 . This enhancing effect of b 5 on CYP2E1 activity is corroborated by others with recombinant enzymes not only for chlorzoxazone 6-hydroxylation (13, 14, 17) but also for aniline p-hydroxylation, N-nitrosodimethylamine-N-demethylation and 7-ethoxycoumarin-O-deethylation (17) .
The role of b 5 on the bioactivation activities of CYP1A2, 2A6 and 2E1 was evaluated with several known procarcinogens with the different BTC strains using the mutagenicity assay. The effect of b 5 on CYP1A2 bioactivation activity was tested with several promutagens. The mutagenicity of 1AP, 6AC, IQ and NNK was not affected by b 5 co-expression. On the other hand, the mutagenicity of 2AA was slightly but significantly increased (~1.5-fold). The enzymatic activities in membranes derived from BTC1A2 and BTC-b 5 -1A2 strains, probed as EROD and MROD, as well as the enzymatic activities of CYP1A2 in other in vitro assays with recombinant or reconstituted enzymes (14, 17) , seem to indicate the absence of any stimulatory effect of b 5 on CYP1A2 activity. However, taking into account the lower RED content presented in strain BTC-b 5 -1A2 when compared with BTC1A2 along with our mutagenicity test results, b 5 might have small stimulatory effects for some substrates as was demonstrated with 2AA in this study.
The stimulatory role of b 5 on CYP2A6 and CYP2E1 bioactivation activities was much more pronounced. The mutagenicity of NNdEA increased 23-fold when b 5 was co-expressed with CYP2A6 and 3-fold when co-expressed with CYP2E1. The CYP2A6-dependent mutagenicity of NNK increased 9-fold when this CYP was co-expressed with b 5 these two CYP forms was co-expressed with b 5 . Stimulation of the CYP2E1-mediated activation of NNdEA and NNdPA by b 5 was reported earlier by Cooper and Porter (15) with a S.typhimurium strain co-expressing b 5 , CYP2E1 and RED, although in this tester bacterium neither CYP2E1 nor b 5 expression could be quantified, hampering a physiologically relevant interpretation. Several recent studies have been reported on the stimulatory role of b 5 on specific CYP forms. These include in vitro assays with reconstituted, recombinant enzymes (11, 12, 14) or studies in whole bacterial cells co-expressing b 5 with RED and CYP (12, 15, 16, 19) . However, in these systems, either the RED:CYP and/or b 5 :CYP ratio(s) were not determined or were higher than those found in human liver microsomes (28--30) . It is known that the turnover of CYPs in human liver microsomes is affected by several factors that are biochemically distinct from the CYP enzyme itself, such as the concentration of the electron transfer proteins RED and/or b 5 . Moreover, it is recognized that multiple CYPs compete for the accessory proteins RED and b 5 in human liver (30) . When using in vitro systems for the study of the role of CYP biotransformation in xenobiotic metabolism, special attention should be given to the relative concentrations of CYPs and the accessory proteins RED and b 5 . This is necessary for qualifying the physiological relevance of such systems. In the human liver, the relative RED:CYP and b 5 :CYP contents can be determined, either for each one of the CYP forms or using the total CYP concentration. The latter method was applied as it mimics the in vivo situation where all CYPs compete for RED and for b 5 . The BTC-b 5 -CYP system described here contains RED:CYP and b 5 :CYP ratios which approximate those found in human liver microsomes (Table IV) and thus, these tester strains mimic human liver microsomes almost exactly. Moreover, in studies using relatively high (41) RED:CYP ratios (vide supra), the stimulatory role of b 5 on CYP activities might not be apparent owing to excessive RED content. This high content may mask the role of b 5 in electron transfer facilitation, one of its presumed functional mechanisms in the multimolecular CYP-complex.
In conclusion, in this work we established three new bioactivation tester strains, for the co-expression of human b 5 with CYP1A2, 2A6 or 2E1 and RED with relative expression levels of these human proteins relevant to the in vivo situation. A strong stimulatory effect of b 5 on CYP2A6 and 2E1 bioactivation activities could be demonstrated with these new strains, which was less pronounced for CYP1A2. To our knowledge, this is the first report of a stimulatory effect of b 5 on CYP2A6 bioactivation activity. The total dependence of NNdPA mutagenicity on b 5 through CYP2A6 and CYP2E1-mediated bioactivation in these tester bacteria is demonstrated. Moreover, the importance of b 5 in the CYP2A6-mediated mutagenicity of the tobacco mutagen NNK (9-fold increase) is described here. The results demonstrated here characterize BTC-b 5 as a strain of interest for studies on the relevance of b 5 on the bioactivation of chemicals by cytochrome P450. Currently, this newly developed BTC-b5 strain is being applied for the study of the role of b5 in the bioactivation of other human CYPs, which are of relevance in xenobiotic biotransformation, such as CYP3A4 and others.
